Clinical Trials Browser

Phase 2 × Dasatinib × Head & Neck × Clear all

NCT05724329 2024-09-19

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT00859937 2018-04-20

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Phase 2 Completed

55 enrolled 8 charts

Salivary Gland Neoplasms

NCT01488318 2018-01-05

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Phase 2 Terminated

21 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT00507767 2014-10-01

Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed

15 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms